For BPC-157, interpretation typically depends on downstream cellular outcomes such as migration, viability, endothelial tube formation, cytoprotection-associated endpoints, or tissue-model measurements
Current research does not conclusively show that medically supervised GHK-Cu therapy causes cancer
A nuanced understanding of safe exposure thresholds and patient-specific susceptibility factors will be critical to ensure that EMF-based modalities do not inadvertently heighten the risk of secondary malignancies or other adverse outcomes
A few states layer their own restrictions on top of FDA's 503A list
Researchers should follow recommended laboratory storage procedures to preserve solution quality
There is no established research on long-term, uninterrupted human use, so cycling is the prudent approach